TARA Opaleye Management Inc. sells $56K worth of shares
Sep 13, 2024, 12:31 AM
-6.08%
What does TARA do
Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
Opaleye Management Inc. sold 32,600 shares of TARA on 11 September at $1.71 per share, worth a total of $56K. They now own 2,063,935 TARA shares, or a 39% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
